Four year trend of carbapenem-resistance in newly opened ICUs of a University-Affiliated Hospital of South Korea

Tuberculosis and Respiratory Diseases

Volumn 72, Issue 4, 2012, Pages 360-366

  Kim, Bo Min ^a   Jeon, Eun Ju ^a   Jang, Ju Young ^a   Chung, Jin Won ^a   Park, Jihoon ^a   Choi, Jae Chol ^a   Shin, Jong Wook ^a   Park, In Won ^a   Choi, Byoung Whui ^a   Kim, Jae Yeol ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

Carbapenems; Drug resistance, bacterial; Intensive care units

Indexed keywords

AMIKACIN; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; ISEPAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA; SOUTH KOREA; UNIVERSITY HOSPITAL;

EID: 84867452649     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2012.72.4.360     Document Type: Article

References (18)

1. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848-54. (Pubitemid 41266753)
2. Song JH. Current status and future strategies of antimicrobial resistance in Korea. Korean J Med 2009;77: 143-51.
3. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289: 885-8. (Pubitemid 37430348)
4. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7. (Pubitemid 38879546)
5. Lee K, Lee HS, Jang SJ, Park AJ, Lee MH, Song WK, et al. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J Korean Med Sci 2001;16:262-70. (Pubitemid 33741029)
6. Dubois V, Arpin C, Melon M, Melon B, Andre C, Frigo C, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of ce-fepime- amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001;39:2072-8. (Pubitemid 32531461)
7. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57:207-15. (Pubitemid 46135866)
8. Agodi A, Zarrilli R, Barchitta M, Anzaldi A, Di Popolo A, Mattaliano A, et al. Alert surveillance of intensive care unit-acquired Acinetobacter infections in a Sicilian hospital. Clin Microbiol Infect 2006;12:241-7. (Pubitemid 43379325)
9. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32 Suppl 2:S94-103.
10. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo: WHO; 2011 [cited 2011 Dec 1]. Available from: http://www. whocc.no/atcddd/.
11. Norrby SR. Carbapenems. Med Clin North Am 1995; 79:745-59.
12. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006;57:1-3. (Pubitemid 43057051)
13. Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii : risk factors and prognosis. Clin Infect Dis 1995;20:790-6.
14. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-92. (Pubitemid 29266004)
15. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004;42:5094-101. (Pubitemid 39506216)
16. Agarwal R, Gupta D, Ray P, Aggarwal AN, Jindal SK. Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in North India. J Infect 2006;53:98-105. (Pubitemid 44028674)
17. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57:557-61. (Pubitemid 43240210)
18. Koeleman JG, Parlevliet GA, Dijkshoorn L, Savelkoul PH, Vandenbroucke-Grauls CM. Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 1997;37:113-23. (Pubitemid 27472627)